Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in J Immunol Retrieve available abstracts of 8 articles: HTML format

Single Articles

March 2025
1. SNYDER M, Wang Z, Lara B, Fimbres J, et al
   The aryl hydrocarbon receptor controls IFN-gamma-induced immune checkpoints PD-L1 and IDO via the JAK/STAT pathway in lung adenocarcinoma.
   J Immunol. 2025;214:413-432.
   PubMed     Abstract available
   
   
   November 2024
2. MA B, Kamle S, Sadanaga T, Lee CM, et al
   Chitinase 3-like-1 Inhibits Innate Antitumor and Tissue Remodeling Immune Responses by Regulating CD47-SIRPalpha- and CD24-Siglec10-Mediated Phagocytosis.
   J Immunol. 2024;213:1279-1291.
   PubMed     Abstract available
   
   
   October 2024
3. OZAKINCI H, Song X, Nazario GS, Lila T, et al
   Rapid Autopsy to Define Dendritic Cell Spatial Distribution and T Cell Association in Lung Adenocarcinoma.
   J Immunol. 2024;213:1033-1041.
   PubMed     Abstract available
   
   
   September 2024
4. DIAMANTOPOULOS N, Li J, Bouchard A, Joumier L, et al
   ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations.
   J Immunol. 2024;213:753-762.
   PubMed     Abstract available
   
   
   July 2024
5. SHANAHAN SL, Kunder N, Inaku C, Hagan NB, et al
   Longitudinal Intravascular Antibody Labeling Identified Regulatory T Cell Recruitment as a Therapeutic Target in a Mouse Model of Lung Cancer.
   J Immunol. 2024 Jul 31:ji2400268. doi: 10.4049/jimmunol.2400268.
   PubMed     Abstract available
   
   
   May 2024
6. SAXENA R, Bushey RT, Campa MJ, Gottlin EB, et al
   Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody.
   J Immunol. 2024;212:1589-1601.
   PubMed     Abstract available
   
   
   January 2024
7. TOYOFUKU T, Ishikawa T, Nojima S, Kumanogoh A, et al
   Efficacy against Lung Cancer Is Augmented by Combining Aberrantly N-Glycosylated T Cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor.
   J Immunol. 2024 Jan 12:ji2300618. doi: 10.4049/jimmunol.2300618.
   PubMed     Abstract available
   
   
   October 2023
8. RAV E, Maegawa S, Gopalakrishnan V, Gordon N, et al
   Overview of CD70 as a Potential Therapeutic Target for Osteosarcoma.
   J Immunol. 2023;211:1067-1072.
   PubMed     Abstract available
   
   

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.